Does Opetha’s 365% stock surge show signs of another potential Cochlear?

Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Opthea is a Melbourne biotechnological company that focuses on developing a treatment for eye diseases. Opthea’s drug OPT 302 focuses on improving vision for two groups. The elderly who suffer […]